References
- González-Duarte A, Cárdenas-Soto K, Bañuelos CE, et al. Amyloidosis due to TTR mutations in Mexico with 4 distinct genotypes in the index cases. Orphanet J Rare Dis. 2018;13:107.
- Merlini G, Planté-Bordeneuve V, Judge D, at al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Trans Res. 2013;6:1011–1020.
- Wilczek HE, Larsson M, Ericzon BG. Long term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid. 2011;18:193–195.
- Ando Y, Sekijima Y, Obayashi K, et al. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open label study. J Neurol Sci. 2016;362:266–271.
- Vinik EJ, Vinik AI, Paulson JF, et al. Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2014;19:104–114.